SONN - Sonnet Biotherapeutics Holdings - Stock Forecast

Coverage Performance Price Targets & Ratings Chart Insider Trading

SONN is currently covered by 2 analysts with an average price target of $235.62. This is a potential upside of $233.92 (13760%) from yesterday's end of day stock price of $1.7.

Sonnet Biotherapeutics Holdings's activity chart (see below) currently has 1 price targets and 9 ratings on display. The stock rating distribution of SONN is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 50% with an average time for these price targets to be met of 20 days.

Highest price target for SONN is $36, Lowest price target is $2, average price target is $235.62.

Most recent stock forecast was given by KEAY NAKAE from CHARDAN CAPITAL on 15-Feb-2024. First documented stock forecast 16-Dec-2021.

Best performing analysts who are covering SONN - Sonnet Biotherapeutics Holdings:

Keay Nakae Michael King

Currently out of the existing stock ratings of SONN, 8 are a BUY (100%).

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

2 months 8 days ago

1/1 (100%)

$8.14 (22.70%)

40

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is SONN (Sonnet Biotherapeutics Holdings) average time for price targets to be met?

On average it took 20 days on average for the stock forecasts to be realized with a an average price target met ratio 50

Which analyst has the current highest performing score on SONN (Sonnet Biotherapeutics Holdings) with a proven track record?

KEAY NAKAE

Which analyst has the current lower performing score on SONN (Sonnet Biotherapeutics Holdings) with a proven track record?

MICHAEL KING

Which analyst has the most public recommendations on SONN (Sonnet Biotherapeutics Holdings)?

Keay Nakae works at CHARDAN CAPITAL and has 7 price targets and 5 ratings on SONN

Which analyst is the currently most bullish on SONN (Sonnet Biotherapeutics Holdings)?

Michael King with highest potential upside - $0

Which analyst is the currently most reserved on SONN (Sonnet Biotherapeutics Holdings)?

Keay Nakae with lowest potential downside - -$0

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?